Navin Fluorine International Limited (NSE:NAVINFLUOR)

Aerovate Therapeutics Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	25,511	23,494	20,650	20,774	14,534	11,794
Revenue Growth (YoY)	21.62%	13.77%	-0.60%	42.94%	23.23%	11.10%
Cost of Revenue	11,415	10,641	9,541	9,104	6,773	5,463
Gross Profit	14,096	12,852	11,109	11,670	7,761	6,331
Selling, General & Admin	2,974	2,980	2,871	2,503	1,828	1,421
Other Operating Expenses	4,583	4,397	4,107	3,512	2,252	1,696
Operating Expenses	8,837	8,572	7,940	6,641	4,558	3,559
Operating Income	5,260	4,281	3,169	5,029	3,203	2,771
Interest Expense	-926.8	-779.3	-745.6	-275.2	-19	-18.4
Interest & Investment Income	22.1	22.1	212.7	39.9	219.8	535.8
Earnings From Equity Investments	-0.3	-0.2	-0.1	-0.1	-0.1	104.7
Currency Exchange Gain (Loss)	3	3	11.3	28.4	-9.3	19
Other Non Operating Income (Expenses)	49.1	12.6	32.8	16.8	23.8	12.4
EBT Excluding Unusual Items	4,407	3,539	2,680	4,839	3,418	3,425
Gain (Loss) on Sale of Investments	261.2	261.2	162.9	100.1	29	104.4
Gain (Loss) on Sale of Assets	0.7	0.7	-8.9	19.7	-4.7	-1.4
Other Unusual Items	-	-	521.3	-	-	155.1
Pretax Income	4,669	3,801	3,355	4,959	3,442	3,683
Income Tax Expense	1,123	914.9	650.3	1,207	811.5	1,108
Earnings From Continuing Operations	3,545	2,886	2,705	3,752	2,631	2,575
Net Income	3,545	2,886	2,705	3,752	2,631	2,575
Net Income to Common	3,545	2,886	2,705	3,752	2,631	2,575
Net Income Growth	36.27%	6.68%	-27.90%	42.62%	2.15%	-36.97%
Shares Outstanding (Basic)	50	50	50	50	50	49
Shares Outstanding (Diluted)	50	50	50	50	50	50
Shares Change (YoY)	0.08%	-0.01%	-0.18%	0.34%	0.00%	0.10%
EPS (Basic)	71.49	58.20	54.57	75.70	53.12	52.03
EPS (Diluted)	71.41	58.14	54.49	75.44	53.08	51.96
EPS Growth	36.17%	6.70%	-27.77%	42.13%	2.16%	-37.04%
Free Cash Flow	-	96.7	175	-8,213	-5,041	1,386
Free Cash Flow Per Share	-	1.95	3.52	-165.15	-101.72	27.96
Dividend Per Share	-	12.000	12.000	12.000	11.000	11.000
Dividend Growth	-	-	-	9.09%	-	-
Gross Margin	55.26%	54.71%	53.80%	56.18%	53.40%	53.68%
Operating Margin	20.62%	18.22%	15.35%	24.21%	22.04%	23.50%
Profit Margin	13.90%	12.28%	13.10%	18.06%	18.10%	21.83%
Free Cash Flow Margin	-	0.41%	0.85%	-39.53%	-34.69%	11.75%
EBITDA	6,403	5,371	4,049	5,594	3,606	3,140
EBITDA Margin	25.10%	22.86%	19.61%	26.93%	24.81%	26.62%
D&A For EBITDA	1,144	1,091	880	564.8	403	368.2
EBIT	5,260	4,281	3,169	5,029	3,203	2,771
EBIT Margin	20.62%	18.22%	15.35%	24.21%	22.04%	23.50%
Effective Tax Rate	24.06%	24.07%	19.38%	24.34%	23.57%	30.08%
Revenue as Reported	25,985	23,931	21,209	21,131	14,926	12,584

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.